MedPath

Biocon Biologics Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

5

FDA:5

Drug Approvals

OGIVRI

Approval Date
Jan 24, 2024
FDA

HULIO

Approval Date
Dec 30, 2023
FDA

Fulphila

Approval Date
Dec 5, 2023
FDA

SEMGLEE

Approval Date
Jul 28, 2023
FDA

Insulin Glargine

Approval Date
Jul 28, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Phase 3
Completed
Conditions
Moderate Chronic Plaque Psoriasis
Severe Chronic Plaque Psoriasis
Interventions
First Posted Date
2022-12-05
Last Posted Date
2024-10-22
Lead Sponsor
Biocon Biologics Inc.
Target Recruit Count
374
Registration Number
NCT05637515
Locations
🇧🇬

Site 407 - Medical Centre "Asklepii", OOD, Dupnitsa, Bulgaria

🇧🇬

Site 409 - Medical center Medconsult Pleven OOD, Pleven, Bulgaria

🇧🇬

Site 403 - MC Rusemed ltd., Ruse, Bulgaria

and more 33 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.